Literature DB >> 18991567

Notch signaling: a potential therapeutic target in prostate cancer.

M A Villaronga1, C L Bevan, B Belandia.   

Abstract

The Notch pathway and the endocrine system constitute two key biological signaling mechanisms, responsible for cell-to-cell communication between adjacent cells and long-distance hormonal signals respectively. They play central roles during the development of higher eukaryotic organisms but they also take part in the regulation of many aspects of adult physiology and homeostasis. The contribution of defects in the normal transmission of hormone-dependent signals to the development of endocrine cancers has been widely analyzed and the knowledge derived from these studies has allowed us to develop many successful therapeutic strategies. However, in many cases these hormonal treatments become ineffective despite the fact that cancer cells maintain normal expression levels of wild-type hormone nuclear receptors. Less is known about the involvement of altered Notch signaling in the origin and progression of cancer, although there is clear evidence indicating that deregulation of Notch activity occurs in several types of tumors, including highly prevalent hormone-dependent types of cancer such as breast, ovarian and prostate cancer. This review will summarize accumulating data suggesting that Notch signaling plays a key role in the control of proliferation, differentiation and survival of prostate epithelial cells. Notch signals are required for normal prostate development and homeostasis, and abnormalities in Notch signaling may be critical during the development of prostate cancer. We will also discuss the possible oncogenic role for alterations in the crosstalk mechanisms between Notch and androgen-dependent signals during tumorigenesis in the prostate and how they could influence the outcome of anti-cancer hormonal treatments.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18991567     DOI: 10.2174/156800908786241096

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  26 in total

Review 1.  Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.

Authors:  Jiao Zhang; Yan-Hua Chen; Qun Lu
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

Review 2.  Hypoxia, notch signalling, and prostate cancer.

Authors:  Laure Marignol; Karla Rivera-Figueroa; Thomas Lynch; Donal Hollywood
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

3.  Silencing Notch-1 induces apoptosis and increases the chemosensitivity of prostate cancer cells to docetaxel through Bcl-2 and Bax.

Authors:  Qi-Fa Ye; Yi-Chuan Zhang; Xiao-Qing Peng; Zhi Long; Ying-Zi Ming; Le-Ye He
Journal:  Oncol Lett       Date:  2012-01-17       Impact factor: 2.967

Review 4.  Therapeutic targeting of the prostate cancer microenvironment.

Authors:  Maria Karlou; Vassiliki Tzelepi; Eleni Efstathiou
Journal:  Nat Rev Urol       Date:  2010-09       Impact factor: 14.432

5.  Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness.

Authors:  Maria Kashat; Lyna Azzouz; Shaan H Sarkar; Dejuan Kong; Yiwei Li; Fazlul H Sarkar
Journal:  Am J Transl Res       Date:  2012-10-10       Impact factor: 4.060

Review 6.  Skp2: a novel potential therapeutic target for prostate cancer.

Authors:  Zhiwei Wang; Daming Gao; Hidefumi Fukushima; Hiroyuki Inuzuka; Pengda Liu; Lixin Wan; Fazlul H Sarkar; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2011-09-22

7.  Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer.

Authors:  Daniel Gioeli; Winfried Wunderlich; Judith Sebolt-Leopold; Stefan Bekiranov; Julia D Wulfkuhle; Emanuel F Petricoin; Mark Conaway; Michael J Weber
Journal:  Mol Cancer Ther       Date:  2011-06-28       Impact factor: 6.261

8.  Down-regulation of Notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells.

Authors:  Zhiwei Wang; Yiwei Li; Aamir Ahmad; Sanjeev Banerjee; Asfar S Azmi; Dejuan Kong; Christine Wojewoda; Lucio Miele; Fazlul H Sarkar
Journal:  J Cell Biochem       Date:  2011-01       Impact factor: 4.429

9.  Repression of androgen receptor activity by HEYL, a third member of the Hairy/Enhancer-of-split-related family of Notch effectors.

Authors:  Derek N Lavery; M Angeles Villaronga; Marjorie M Walker; Anup Patel; Borja Belandia; Charlotte L Bevan
Journal:  J Biol Chem       Date:  2011-03-17       Impact factor: 5.157

10.  Delta/notch-like epidermal growth factor-related receptor (DNER) orchestrates stemness and cancer progression in prostate cancer.

Authors:  Lijun Wang; Qi Wu; Shan Zhu; Zhiyu Li; Jingping Yuan; Dehua Yu; Zhiliang Xu; Juanjuan Li; Shengrong Sun; Changhua Wang
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.